2026-04-17T05:44:39Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/108722025-10-24T10:35:11Zcom_2072_378070com_2072_378040col_2072_378092

2025-10-24T10:35:11Z urn:hdl:11351/10872 Crossing barriers: the burden of inflammatory bowel disease across Western Europe Kumar, Aditi Yassin, Nuha Marley, Alexandra Bellato, Vittoria Foppa, Caterina Pellino, Gianluca Intestins - Inflamació - Tractament Assistència sanitària - Cost DISEASES::Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Inflammatory Bowel Diseases Other subheadings::Other subheadings::/therapy HEALTH CARE::Health Care Economics and Organizations::Economics::Costs and Cost Analysis::Health Care Costs ENFERMEDADES::enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::enfermedad inflamatoria intestinal Otros calificadores::Otros calificadores::/terapia ATENCIÓN DE SALUD::economía y organizaciones para la atención de la salud::economía::costes y análisis de costes::costes de la atención a la salud Disease burden; Healthcare; Inflammatory bowel disease Càrrega de la malaltia; Atenció sanitària; Malaltia inflamatòria de l'intestí Carga de la enfermedad; Atención sanitaria; Enfermedad inflamatoria intestinal An estimated 2.5–3 million individuals (0.4%) in Europe are affected by inflammatory bowel disease (IBD). Whilst incidence rates for IBD are stabilising across Europe, the prevalence is rising and subsequently resulting in a significant cost to the healthcare system of an estimated 4.6–5.6 billion euros per year. Hospitalisation and surgical resection rates are generally on a downward trend, which is contrary to the rising cost of novel medication. This signifies a large part of healthcare cost and burden. Despite publicly funded healthcare systems in most European countries, there is still wide variation in how patients receive and/or pay for biologic medication. This review will provide an overview and discuss the different healthcare systems within Western Europe and the barriers that affect overall management of a changing IBD landscape, including differences to hospitalisation and surgical rates, access to medication and clinical trial participation and recruitment. This review will also discuss the importance of standardising IBD management to attain high-quality care for all patients with IBD. 2025-10-24T10:35:11Z 2025-10-24T10:35:11Z 2024-01-16T13:07:11Z 2024-01-16T13:07:11Z 2023 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/10872 Therapeutic Advances in Gastroenterology;16 https://doi.org/10.1177/17562848231218615 Attribution-NonCommercial 4.0 International http://creativecommons.org/licenses/by-nc/4.0/ info:eu-repo/semantics/openAccess SAGE Publications Scientia